ReviewDigestive diseases and sciences2018
Advanced Strategies for Eliminating the cccDNA of HBV.
Review in Digestive diseases and sciences, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- [The E3 ubiquitin ligase KLHL8 degrades HBx protein via the ubiquitin-proteasome pathway and inhibits HBV cccDNA transcription].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
- A sequence-specific, nanoparticle-based biosensor platform for rapid and visual identification of serum hepatitis B virus pregenomic RNA in chronic hepatitis B patients.Microbiology spectrum · 2026Article
- Challenges and Solutions in pgRNA Measurement: Toward Improved Monitoring of Hepatitis B Therapy.Pathogens (Basel, Switzerland) · 2026Review
- A study on pregenomic RNA and factors in the pregnant and postpartum women with chronic HBV infection based on real world.Frontiers in cellular and infection microbiology · 2025Article
- Review
- The Levels of Serum HBV Pre-Genomic RNA and Its Associated Factors Among HBV-Infected Patients: A Retrospective Cohort Study in Hangzhou, Zhejiang, China.International journal of general medicine · 2024Article
- HBV pregenome RNA as a predictor of spontanous HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients.BMC gastroenterology · 2023Article
- Drug Discovery Study Aimed at a Functional Cure for HBV.Viruses · 2022Review
- Inhaled siRNA Formulations for Respiratory Diseases: From Basic Research to Clinical Application.Pharmaceutics · 2022Review
- A Study on Pregenomic RNA and Factors Related to Hepatitis B Virus Infection Based on Real World.Frontiers in public health · 2022Article
- Role of epigenetic modification in interferon treatment of hepatitis B virus infection.Frontiers in immunology · 2022Review
- Higher titer hepatitis B core antibody predicts a higher risk of liver metastases and worse survival in patients with colorectal cancer.World journal of surgical oncology · 2021Article
- Hepatitis B virus-host interactions and novel targets for viral cure.Current opinion in virology · 2021Review
- Recent Advances in Understanding, Diagnosing, and Treating Hepatitis B Virus Infection.Microorganisms · 2020Review
- Host-Directed Antiviral Therapy.Clinical microbiology reviews · 2020Review
- Diagnostic Value of Detection of Pregenomic RNA in Sera of Hepatitis B Virus-Infected Patients with Different Clinical Outcomes.Journal of clinical microbiology · 2020Article
- Mapping the Interactions of HBV cccDNA with Host Factors.International journal of molecular sciences · 2019Review
- Factors associated with disease progression and viral replication in patients with chronic hepatitis B virus infection.Experimental and therapeutic medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Persistent hepatitis B virus (HBV) infection of hepatocytes is associated with a covalently closed circular DNA (cccDNA) episome. Although serologic hepatitis B surface antigen tests are negative, the presence of cccDNA is obviously increased in HBeAg-positive patients compared with that in HBeAg-negative patients, inactive carriers and patients. Moreover, trace cccDNA levels can also be found in the liver cells of patients with resolved hepatitis B infections. Therefore, clearance of cccDNA in hepatocytes could be an effective cure for HBV. In this review, we summarize the strategies that have been employed to eliminate cccDNA in recent years and discuss the future development of treatments for chronic hepatitis B.
Indexed as
Identifiers
29159681What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.